Plasma-derived small extracellular vesicles unleash the angiogenic potential in head and neck cancer patients.
Luisa TenglerJulia SchützMoritz TiedtkeJadwiga JablonskaMarie-Nicole TheodorakiKatja NitschkeChristel WeißElena SeizAnnette AffolterFrederic JungbauerAnne LammertNicole RotterSonja LudwigPublished in: Molecular medicine (Cambridge, Mass.) (2023)
In general, plasma sEVs carry a predominantly anti-angiogenic protein cargo and suppress the angiogenic properties of ECs, while sEVs from (advanced-stage) HNC patients induce angiogenesis compared to HD sEVs. Thus, tumor-derived sEVs within the plasma of HNC patients might shift the angiogenic switch towards angiogenesis.